Reconsidering the role of blood-brain barrier in Alzheimer's disease: From delivery to target

被引:22
|
作者
Sousa, Joao Andre [1 ]
Bernardes, Catarina [1 ]
Bernardo-Castro, Sara [1 ,2 ]
Lino, Miguel [3 ]
Albino, Ines [3 ]
Ferreira, Lino [2 ,3 ]
Bras, Jose [4 ]
Guerreiro, Rita [4 ]
Tabuas-Pereira, Miguel [1 ,2 ]
Baldeiras, Ines [2 ,5 ]
Santana, Isabel [1 ,2 ,5 ]
Sargento-Freitas, Joao [1 ,2 ,3 ,5 ]
机构
[1] Ctr Hosp & Univ Coimbra, Dept Neurol, Coimbra, Portugal
[2] Univ Coimbra, Fac Med, Coimbra, Portugal
[3] Univ Coimbra, Ctr Neurosci & Cell Biol, Coimbra, Portugal
[4] Van Andel Inst, Dept Neurodegenerat Sci, Grand Rapids, MI USA
[5] Univ Coimbra, Ctr Innovat Biomed & Biotechnol CIBB, Coimbra, Portugal
来源
FRONTIERS IN AGING NEUROSCIENCE | 2023年 / 15卷
关键词
blood-brain barrier; nanomaterials; Alzheimer's disease; neurodegenerative diseases; amyloid clearance; genetic targeting; AMYLOID-BETA; MOUSE MODEL; NEUROVASCULAR DYSFUNCTION; DRUG-DELIVERY; THERAPEUTIC STRATEGIES; COGNITIVE IMPAIRMENT; P-GLYCOPROTEIN; CLEARANCE; RAGE; FLOW;
D O I
10.3389/fnagi.2023.1102809
中图分类号
R592 [老年病学]; C [社会科学总论];
学科分类号
03 ; 0303 ; 100203 ;
摘要
The existence of a selective blood-brain barrier (BBB) and neurovascular coupling are two unique central nervous system vasculature features that result in an intimate relationship between neurons, glia, and blood vessels. This leads to a significant pathophysiological overlap between neurodegenerative and cerebrovascular diseases. Alzheimer's disease (AD) is the most prevalent neurodegenerative disease whose pathogenesis is still to be unveiled but has mostly been explored under the light of the amyloid-cascade hypothesis. Either as a trigger, bystander, or consequence of neurodegeneration, vascular dysfunction is an early component of the pathological conundrum of AD. The anatomical and functional substrate of this neurovascular degeneration is the BBB, a dynamic and semi-permeable interface between blood and the central nervous system that has consistently been shown to be defective. Several molecular and genetic changes have been demonstrated to mediate vascular dysfunction and BBB disruption in AD. The isoform epsilon 4 of Apolipoprotein E is at the same time the strongest genetic risk factor for AD and a known promoter of BBB dysfunction. Low-density lipoprotein receptor-related protein 1 (LRP-1), P-glycoprotein, and receptor for advanced glycation end products (RAGE) are examples of BBB transporters implicated in its pathogenesis due to their role in the trafficking of amyloid-beta. This disease is currently devoid of strategies that change the natural course of this burdening illness. This unsuccess may partly be explained by our misunderstanding of the disease pathogenesis and our inability to develop drugs that are effectively delivered to the brain. BBB may represent a therapeutic opportunity as a target itself or as a therapeutic vehicle. In this review, we aim to explore the role of BBB in the pathogenesis of AD including the genetic background and detail how it can be targeted in future therapeutic research.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] Drug delivery to the brain in Alzheimer's disease: Consideration of the blood-brain barrier
    Banks, William A.
    ADVANCED DRUG DELIVERY REVIEWS, 2012, 64 (07) : 629 - 639
  • [2] Role of the blood-brain barrier in Alzheimer's disease
    Gosselet, Fabien
    Candela, Pietra
    Cecchelli, Romeo
    Fenart, Laurence
    M S-MEDECINE SCIENCES, 2011, 27 (11): : 987 - 992
  • [3] Role of Blood-Brain Barrier in Alzheimer's Disease
    Cai, Zhiyou
    Qiao, Pei-Feng
    Wan, Cheng-Qun
    Cai, Min
    Zhou, Nan-Kai
    Li, Qin
    JOURNAL OF ALZHEIMERS DISEASE, 2018, 63 (04) : 1223 - 1234
  • [4] Blood-brain barrier integrity in the pathogenesis of Alzheimer's disease
    Huang, Zhangsen
    Wong, Lik-Wei
    Su, Yixun
    Huang, Xiaomin
    Wang, Nan
    Chen, Hui
    Yi, Chenju
    FRONTIERS IN NEUROENDOCRINOLOGY, 2020, 59
  • [5] siRNA drug delivery across the blood-brain barrier in Alzheimer's disease
    Sajid, Muhammad Imran
    Sheikh, Fahad Sultan
    Anis, Faiza
    Nasim, Nourina
    Sumbria, Rachita K.
    Nauli, Surya M.
    Tiwari, Rakesh Kumar
    ADVANCED DRUG DELIVERY REVIEWS, 2023, 199
  • [6] Addressing Blood-Brain Barrier Impairment in Alzheimer's Disease
    Sharma, Chanchal
    Woo, Hanwoong
    Kim, Sang Ryong
    BIOMEDICINES, 2022, 10 (04)
  • [7] Blood-brain barrier P-glycoprotein function in Alzheimer's disease
    van Assema, Danielle M. E.
    Lubberink, Mark
    Bauer, Martin
    van der Flier, Wiesje M.
    Schuit, Robert C.
    Windhorst, Albert D.
    Comans, Emile F. I.
    Hoetjes, Nikie J.
    Tolboom, Nelleke
    Langer, Oliver
    Mueller, Markus
    Scheltens, Philip
    Lammertsma, Adriaan A.
    van Berckel, Bart N. M.
    BRAIN, 2012, 135 : 181 - 189
  • [8] Relationship Between Amyloid-β Deposition and Blood-Brain Barrier Dysfunction in Alzheimer's Disease
    Wang, Dong
    Chen, Fanglian
    Han, Zhaoli
    Yin, Zhenyu
    Ge, Xintong
    Lei, Ping
    FRONTIERS IN CELLULAR NEUROSCIENCE, 2021, 15
  • [9] Treatment of Alzheimer's Disease and Blood-Brain Barrier Drug Delivery
    Pardridge, William M.
    PHARMACEUTICALS, 2020, 13 (11) : 1 - 25
  • [10] Role of the blood-brain barrier in the pathogenesis of Alzheimer's disease
    Deane, Rashid
    Zlokovic, Berislav V.
    CURRENT ALZHEIMER RESEARCH, 2007, 4 (02) : 191 - 197